Anginovag spray oromucosal

Quốc gia: Armenia

Ngôn ngữ: Tiếng Anh

Nguồn: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Thành phần hoạt chất:

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Sẵn có từ:

Ferrer Internacional

Mã ATC:

առկա չէ (R02A)

INN (Tên quốc tế):

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Liều dùng:

1mg/ml+ 4mg/ml+ 0.6mg/ml+ 0.6mg/ml+ 1mg/ml

Dạng dược phẩm:

spray oromucosal

Các đơn vị trong gói:

20ml (200 doses) plastic container and pump dispenser

Loại thuốc theo toa:

OTC

Tình trạng ủy quyền:

Registered

Ngày ủy quyền:

2020-12-30

Đặc tính sản phẩm

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ANGINOVAG Oromucosal spray solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition per 1 ml :
Dequalinium chloride
....................................................................................................................
1,0 mg
Enoxolone
.......................................................................................................................................
0,6 mg
Hydrocortisone acetate
..................................................................................................................
0,6 mg
Tyrothricin
......................................................................................................................................
4,0 mg
Lidocaine hydrochloride
................................................................................................................
1,0 mg
Excipient(s) with known effect :
Propylene glycol and ethanol 96%
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal spray solution.
Clear, colourless or slightly yellow solution
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Preventive and curative therapy of oropharyngeal affections:
Amygdalitis, pharyngitis, laryngitis, stomatitis, oral ulcers and
aphthae, glossitis.
4.2
Posology and method of administration
Posology
Oropharyngeal use.
Adults and children over 13 years old
Attack dose: 1-2 applications every 2-3 hours.
Maintenance or preventive dose: One application every 6 hours.
Paediatric population
The safety and efficacy of Anginovag in children aged under 13 years
old have not yet been
established.
Method of administration
Open the mouth widely. Point the inhaler mouthpiece to the affected
area (throat, mouth, tongue, etc,
depending on the case).
Push the upper part of the cap from top to bottom up to the limit,
keeping the bottle in upright position.
The bottle is supplied with a metering valve: each actuation up to the
limit causes the regulated drug
delivery.
4.3
Contra